ReviewFrontiers in radiology2026
Vietnamese expert consensus on the treatment of hepatocellular carcinoma with transarterial chemoembolization.
Review in Frontiers in radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a major public health challenge in Vietnam and, according to GLOBOCAN 2022, accounted for 24,502 new cases in 2022, making it the second most common cancer and the leading cause of cancer-related mortality. Transarterial chemoembolization (TACE), introduced in 1977, is a pivotal treatment for unresectable HCC, delivering chemotherapeutic agents and embolic materials to induce tumor necrosis through cytotoxicity and ischemia. TACE is versatile and, in selected early-stage HCC (BCLC 0-A) treated with a highly selective approach, may achieve complete response; in intermediate-stage disease (BCLC B), it can prolong survival and enable downstaging, and in advanced-stage disease (BCLC C), it may complement systemic therapy. Despite its global use, TACE practices vary, and Vietnam lacks standardized guidelines tailored to its unique clinical landscape. The Vietnamese Society of Radiology and Nuclear Medicine and The Vietnamese Society of Interventional Radiology conducted three workshops in Da Nang, An Giang, and Can Tho between August and December 2024. These workshops engaged interventional radiologists from major hospitals and regional centers to develop consensus-based TACE recommendations. Through literature reviews, discussions, and physician voting, the recommendations cover pre-TACE diagnostic imaging, patient selection criteria, TACE techniques, choice of embolic materials and chemotherapeutic agents, intra- and post-procedure monitoring, and integration with combination therapies. This initiative aligns international standards with local needs, aiming to enhance the efficacy and consistency of TACE for HCC management in Vietnam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.